Shopping Cart
Remove All
Your shopping cart is currently empty
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $84 | In Stock | In Stock | |
| 5 mg | $197 | In Stock | In Stock | |
| 10 mg | $328 | In Stock | In Stock | |
| 25 mg | $596 | In Stock | In Stock | |
| 50 mg | $896 | In Stock | In Stock | |
| 100 mg | $1,220 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $226 | In Stock | In Stock |
| Description | FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity. |
| Targets&IC50 | FLT3:0.28 nM, CDK2-CyclinA:2.47 nM, CDK6-CyclinD1:1.96 nM, CDK4-CyclinD1:0.85 nM |
| In vitro | FN-1501 displays potent inhibitory activity against several tumor cells, such as MGC803, RS4;11, MCF-7, HCT-116, and NCI-H82 (GI50s of 0.37 ± 0.04, 0.05 ± 0.01, 2.84 ± 0.25, 0.09 ± 0.04, 0.11 ± 0.02 nM, respectively)[1]. |
| In vivo | FN-1501 shows potent antitumor activity and it also shows little cytotoxicity on normal lymphocyte cells (LD50: 185.67 mg/kg in ICR mice). FN-1501 (15. 30, or 40 mg/kg/d, i.v.) dose-dependently and obviously inhibits the growth of tumors in MV4-11-cell-inoculated-xenograft mice[1]. |
| Molecular Weight | 431.49 |
| Formula | C22H25N9O |
| Cas No. | 1429515-59-2 |
| Smiles | CN1CCN(Cc2ccc(NC(=O)c3n[nH]cc3Nc3ncnc4[nH]ccc34)cc2)CC1 |
| Relative Density. | 1.427 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (104.29 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.64 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.